Vanderbilt-Ingram Cancer Center

Quick facts

Marketed products

• Bisphosphonates · Other
• Cetuximab (EGFR inhibitor) · Oncology
  Cetuximab is a monoclonal antibody that binds to and blocks the epidermal growth factor receptor (EGFR), preventing ligand-induced activation and downstream proliferation signaling in cancer cells.
• Copper Cu 64 Dotatate · Oncology
  Copper Cu 64 Dotatate is a radioactive imaging agent that binds to somatostatin receptors on neuroendocrine tumor cells, allowing PET visualization and localization of these tumors.

Phase 3 pipeline

• cyclosporine ophthalmic emulsion · Ophthalmology
  Cyclosporine ophthalmic emulsion works by suppressing the immune system to prevent rejection of transplanted corneal tissue.
• Magic Mouthwash · Oncology
  Magic Mouthwash is a topical oral rinse that combines local anesthetics, antimicrobials, and anti-inflammatory agents to relieve oral mucositis pain and promote healing in cancer patients.
• TGR-1202 · Oncology
  TGR-1202 is a selective inhibitor of the PI3K delta subunit.

Phase 2 pipeline

• Erlotinb · Other
• Hormonal Therapy

Phase 1 pipeline

• Nivo800
• PI3K inhibitor BYL719

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Vanderbilt-Ingram Cancer Center portfolio CI brief
• Vanderbilt-Ingram Cancer Center pipeline updates RSS